OTCMKTS:OTLC Oncotelic Therapeutics Q4 2025 Earnings Report $0.02 0.00 (0.00%) As of 09/18/2026 03:56 PM Eastern ProfileEarnings History Oncotelic Therapeutics EPS ResultsActual EPS$0.59Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOncotelic Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOncotelic Therapeutics Announcement DetailsQuarterQ4 2025Date4/15/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Oncotelic Therapeutics Earnings HeadlinesOncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6thAugust 3, 2026 | financialpost.comFOncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6thAugust 3, 2026 | globenewswire.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade. | The Oxford Club (Ad)Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)July 22, 2026 | globenewswire.comOTLC Share News TodayJuly 14, 2026 | uk.investing.comOncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion UnderwayJuly 7, 2026 | globenewswire.comSee More Oncotelic Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncotelic Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncotelic Therapeutics and other key companies, straight to your email. Email Address About Oncotelic TherapeuticsOncotelic Therapeutics (OTCMKTS:OTLC) is a clinical-stage biotechnology company focused on developing novel therapies for cancer and other serious diseases. The company’s research platform emphasizes RNA-based therapeutics and targets biological pathways involved in tumor growth, immune response, and disease progression. Its principal investigational product is OT-101, also known as trabedersen, an antisense oligonucleotide designed to inhibit transforming growth factor beta 2 (TGF-β2). Oncotelic has studied OT-101 in several oncology settings, including brain and other solid tumors. The company has also explored additional therapeutic programs in areas such as infectious disease and rare disorders, although its pipeline and development priorities may change over time. Oncotelic was formed through the combination of businesses associated with Oncotelic and Mateon Therapeutics and is led by Chief Executive Officer Vuong Trieu. The company conducts research and development through collaborations and clinical activities intended to support the advancement of its investigational medicines. Its products remain in development and are not broadly marketed commercial therapies.View Oncotelic Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in Focus Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
